Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma (Q63817414)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma |
clinical trial |
Statements
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies (English)
0 references
March 2011
0 references
June 2014
0 references
564
0 references
18 year
0 references